JP2016502989A - 経皮送達システム - Google Patents

経皮送達システム Download PDF

Info

Publication number
JP2016502989A
JP2016502989A JP2015547016A JP2015547016A JP2016502989A JP 2016502989 A JP2016502989 A JP 2016502989A JP 2015547016 A JP2015547016 A JP 2015547016A JP 2015547016 A JP2015547016 A JP 2015547016A JP 2016502989 A JP2016502989 A JP 2016502989A
Authority
JP
Japan
Prior art keywords
buprenorphine
transdermal therapeutic
therapeutic system
base
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2015547016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502989A5 (enExample
Inventor
ガブリエル・ウォアー
ケヴィン・ジョン・スミス
ジリアン・エリザベス・マンディン
ヘレン・エリザベス・ジョンソン
トーマス・ヒレ
Original Assignee
エルテーエス ローマン テラピー−ジステーメ アーゲー
エルテーエス ローマン テラピー−ジステーメ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49816915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016502989(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エルテーエス ローマン テラピー−ジステーメ アーゲー, エルテーエス ローマン テラピー−ジステーメ アーゲー filed Critical エルテーエス ローマン テラピー−ジステーメ アーゲー
Publication of JP2016502989A publication Critical patent/JP2016502989A/ja
Publication of JP2016502989A5 publication Critical patent/JP2016502989A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015547016A 2012-12-12 2013-12-12 経皮送達システム Abandoned JP2016502989A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736342P 2012-12-12 2012-12-12
US61/736,342 2012-12-12
PCT/EP2013/076325 WO2014090921A1 (en) 2012-12-12 2013-12-12 Transdermal delivery system

Publications (2)

Publication Number Publication Date
JP2016502989A true JP2016502989A (ja) 2016-02-01
JP2016502989A5 JP2016502989A5 (enExample) 2017-01-19

Family

ID=49816915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015547016A Abandoned JP2016502989A (ja) 2012-12-12 2013-12-12 経皮送達システム

Country Status (26)

Country Link
US (3) US20150306093A1 (enExample)
EP (1) EP2931263A1 (enExample)
JP (1) JP2016502989A (enExample)
KR (1) KR20150096460A (enExample)
CN (1) CN105007906A (enExample)
AP (1) AP2015008525A0 (enExample)
AR (1) AR093940A1 (enExample)
AU (1) AU2013205080B2 (enExample)
BR (1) BR112015013660A2 (enExample)
CA (1) CA2894960A1 (enExample)
CL (1) CL2015001577A1 (enExample)
CR (1) CR20150360A (enExample)
DE (1) DE112013005945T5 (enExample)
EA (1) EA201591124A1 (enExample)
GB (1) GB2523715A (enExample)
HK (1) HK1215677A1 (enExample)
IL (1) IL239223A0 (enExample)
MX (1) MX2015007348A (enExample)
NZ (1) NZ628092A (enExample)
PE (1) PE20151147A1 (enExample)
PH (1) PH12015501169A1 (enExample)
SG (1) SG11201504286VA (enExample)
TN (1) TN2015000201A1 (enExample)
TW (1) TW201438765A (enExample)
WO (1) WO2014090921A1 (enExample)
ZA (1) ZA201504964B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP2790685B1 (en) 2011-12-12 2017-08-16 LTS LOHMANN Therapie-Systeme AG Transdermal delivery system comprising buprenorphine
LT2810646T (lt) 2013-06-04 2016-10-25 Lts Lohmann Therapie-Systeme Ag Transderminė tiekimo sistema
SG11201707350TA (en) 2015-03-10 2017-10-30 Rhodes Tech Acetate salt of buprenorphine and methods for preparing buprenorphine
EP3349737A4 (en) * 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC SYSTEM FOR TRANSDERING
KR101695603B1 (ko) * 2016-11-08 2017-01-12 이창우 병목 하단 밀착 구조의 점탄성 연결캡을 포함하는 니들 디스크 롤러 장치
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
BR112020018607A2 (pt) * 2018-03-13 2020-12-29 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone acrílico
CA3092750A1 (en) * 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer
WO2019175106A1 (en) * 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
BR112020018300A2 (pt) * 2018-03-13 2020-12-22 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone e acrílico
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
CN114025748A (zh) * 2019-07-09 2022-02-08 罗曼治疗系统股份公司 包括包含含硅酮聚合物的含活性剂层和包含硅酮凝胶粘合剂的皮肤接触层的透皮治疗系统
CN113952319A (zh) * 2021-11-30 2022-01-21 烟台大学 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
CN1943576A (zh) * 2006-10-27 2007-04-11 哈尔滨健迪医药技术有限公司 丁丙诺啡和/或盐酸丁丙诺啡贴剂基质及其贴剂的制备方法
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
CN101612141B (zh) * 2009-07-29 2012-10-03 考司美德制药株式会社 丁丙诺啡贴剂

Also Published As

Publication number Publication date
DE112013005945T5 (de) 2015-08-27
EA201591124A1 (ru) 2015-11-30
AP2015008525A0 (en) 2015-06-30
EP2931263A1 (en) 2015-10-21
WO2014090921A1 (en) 2014-06-19
US20150306093A1 (en) 2015-10-29
PH12015501169A1 (en) 2015-08-10
ZA201504964B (en) 2017-11-29
CA2894960A1 (en) 2014-06-19
HK1215677A1 (zh) 2016-09-09
GB201512243D0 (en) 2015-08-19
US20180193333A1 (en) 2018-07-12
NZ628092A (en) 2017-01-27
CN105007906A (zh) 2015-10-28
IL239223A0 (en) 2015-07-30
TW201438765A (zh) 2014-10-16
AU2013205080B2 (en) 2016-07-07
AR093940A1 (es) 2015-07-01
US20200253957A1 (en) 2020-08-13
MX2015007348A (es) 2016-01-20
SG11201504286VA (en) 2015-06-29
KR20150096460A (ko) 2015-08-24
CR20150360A (es) 2015-08-21
GB2523715A (en) 2015-09-02
BR112015013660A2 (pt) 2017-07-11
TN2015000201A1 (en) 2016-10-03
AU2013205080A1 (en) 2014-06-26
CL2015001577A1 (es) 2015-10-02
PE20151147A1 (es) 2015-08-06

Similar Documents

Publication Publication Date Title
US20200306204A1 (en) Transdermal delivery system comprising buprenorphine
US20200253957A1 (en) Transdermal delivery system
US12138353B2 (en) Transdermal therapeutic system containing asenapine
HK1203048B (en) Transdermal delivery system comprising buprenorphine
NZ626535B2 (en) Transdermal delivery system comprising buprenorphine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161128

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20170728